<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694224</url>
  </required_header>
  <id_info>
    <org_study_id>SHH (Sonic HedgeHog)-CM</org_study_id>
    <nct_id>NCT02694224</nct_id>
  </id_info>
  <brief_title>Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients</brief_title>
  <acronym>SHH-CM</acronym>
  <official_title>A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of vismodegib with standard neoadjuvant chemotherapy in
      breast cancer patients based on the CTCAE v4 2010

        1. To study changes in biomarkers involved in the Hedgehog (HH) pathway in the first biopsy
           as compared to the later one

        2. To detect predictive factors among patients who reached pathological complete response
           (pCR) as compared to those with no pCR

        3. To evaluate the role of the addition of vismodegib in the pCR rate

        4. To evaluate clinical responses by breast MRI and rates of breast conservative surgery
           after neoadjuvant chemotherapy

        5. To evaluate QOL with EORTC QLQ-C30 scale
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>21 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular changes in breast</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response (cCR)</measure>
    <time_frame>21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality of Life questionnaire C30 (EORTC QOL-C30)</measure>
    <time_frame>30 months</time_frame>
    <description>We will consider data related to quality of life such as weakness, appetite, physical health, physiological health, social relationships, environment etc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>vismodegib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Smo inhibitor</description>
    <arm_group_label>vismodegib plus chemotherapy</arm_group_label>
    <other_name>GDC0449</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support</description>
    <arm_group_label>vismodegib plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel</description>
    <arm_group_label>vismodegib plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel</description>
    <arm_group_label>vismodegib plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female sex

          2. Ability to give informed agreement and to carry out the whole study protocol during
             the study period

          3. The patient should be able to carry out the needs of the clinical trial and have
             measurable disease

          4. The patient should be 18-75 year-old

          5. Triple negative breast cancer (ER&lt;1%, Progesteron Receptor (PR)&lt;1%, non-overexpressing
             HER2). 1. Patients with oligometastatic disease (1-2 resectable metastases) could be
             included

          6. No previous systemic therapies

          7. Patients who are going to benefit from neoadjuvant chemotherapy

          8. Eastern Cooperative Oncology Group (ECOG)&lt;2 or Karnofsky≥70%

          9. Blood tests and biochemistry suitable: (absolute neutrophil count&gt; 1500/uL;
             haemoglobin&gt;9 gr/dL; platelets&gt;100000/uL (microliters); total bilirubin≤ 1.5 the upper
             normal limit; GOT and GPT (transaminases)≤twice the upper normal limit; fasting
             glucose≤150 gr/dL; HbA1c≤8%, serum creatinine≤2 mg/dL.

        Exclusion Criteria:

          1. Severe diseases or infectious diseases or liver, kidney or bone marrow failure that
             advise not to participate in the study according to investigator criteria

          2. Pregnancy or breast feeding period or fertility women who are not agree with
             contraception methods

          3. Other primary tumors except for breast in situ carcinoma (CIS), cervical
             neoplasia(CIN) or localized skin tumors

          4. Inflammatory breast cancer or bilateral breast cancer

          5. Bone fractures, peptic ulcus or healing disorders

          6. Any local or systemic therapy for breast cancer

          7. To be maintained on immunosuppressants (prednisone &gt; 10 mgr daily or others), aspirin&gt;
             325 mgr per day or clopidogrel &gt; 75 mgr daily

          8. Cardiomyopathy by New York Heart Association (NYHA) class II-IV; heart stroke in the
             previous 6 months; uncontrolled blood pressure (systolic &gt; 150 mm Hg and /or diastolic
             &gt; 100 mm Hg), coagulopathy or hemorrhagic diseases

          9. Previous lung diseases

         10. Personal history of abdominal perforation, abdominal abscess, or abdominal fistula.

         11. Inability to swallow pills

         12. Intolerance to galactose, malabsorption to galactose or/and glucose, or primary
             hypolactasia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santisteban Marta, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff of the department of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amaya Izal</last_name>
    <phone>+34948255400</phone>
    <phone_ext>2724</phone_ext>
    <email>aizal@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joana Reis, Nurse</last_name>
    <phone>+34948255400</phone>
    <phone_ext>2759</phone_ext>
    <email>jreis@unav.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amaya Izal</last_name>
      <phone>+34948255400</phone>
      <phone_ext>2724</phone_ext>
      <email>aizal@unav.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>triple negative</keyword>
  <keyword>neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

